Sign up to save your podcasts
Or
Share Should Cost of Therapy Be Considered in CV Guidelines?
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Should Cost of Therapy Be Considered in CV Guidelines?
New cardio drugs, such as PCSK9 inhibitors and the angiotensin receptor neprilysin inhibitor, are expensive. Dr O'Donoghue asks whether that should affect guideline recommendations.
View all episodes
By MedscapeNew cardio drugs, such as PCSK9 inhibitors and the angiotensin receptor neprilysin inhibitor, are expensive. Dr O'Donoghue asks whether that should affect guideline recommendations.